American Thoracic
Society.Standars for the diagnosis and care of patients with chronic
obstructive pulmonary disease (COPD ) and asthma. Am Rev Respir
Dis 1987;136:225-44.
Siafakas NM, Vermeire P , Pride NB, Paoletti P, Gibson J, Howard
P, et al. <<ers consensus statement. Optimal assesment and
management of chronic obstructive pulmonary disease (COPD ). A consensus
statement of the European Respiratory Society ( ERS ). Eur Respir
J 1995;8:1398-420.
Celli BR, Snider GL, Heffner J,Tiep B, Ziment I , Make B, et al.
Standars for the diagnosic and care of patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-S120.
Montemayor Rubio T, Alfajeme Michavilla J, Escudero Bueno C, Morera
Prat J,Sánchez Agudo L.Normativa sobre diagnóstico
y tratamiento de la enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol 1996;32:285-301.
Pauwels RA, Buist AS, Ma P Jenkins CR, Hurd SS. Global strategy
for the diagnosis, manegement, and prevention of chronic obstructive
pulmonary disease:National Heart Lung , and Blood Institute and
World Health Organitation Global Initiative for Chronic Obstructive
Lung Disease (GOLD ): executive summary. Respir Care 2001;46;798-825.
Comité Científico del Estudio IBERPOC. Proyecto IBERPOC:
un estudio epidemiológico de la EPOC en España. Arch
Bronconeumol 1997;33:293-9.
Fletcher C, Peto R, Tinker C. The natural history of chronic bronquitis
and emphysema. Oxford:University Presws; 1976.
Sobradillo V, Miratvilles M, Jiménez CA, Gabriel R, Viejo
JL, Masa JF, et al.Estudio IBERPOC en España: prevalencia
de síntomas respiratorios habituales y de limitación
crónica al flujo aéreo. Arch Bronconeumol 1999;35:159-66.
Doll R, Peto R. Mortality en relation to smoking : 20 years of observations
on male British doctors. Br Med J 1976;2:1525-36.
Wang X, Wipij D, Gold DR, Speizer FE, Ware JH, Ferris BJ Jr, et
al.A longitudinal study of the effects of parental smoking on pulmonary
funtion in children 6-18 years. Am J Respir Crit Care Med 1994;149:1420-5.
Saetta M, Finkelstein R, Cossío MG. Morphologycal and cellular
basis for airflow limitation in smokers. Eur Respir J 1994;7:1505-15.
Pride NB. Pathophysiology. En: Brewis RAL, Corrin B, Geddes DM,
Gibson GJ, editores. Respiratory medicine. 2nd ed. London: WB Saunders
Co;1995;p.1054-69.
Melero C.Enfermedad Pulmonar Obstructiva Crónica. En :Habilidades
en Patología Infecciosa Respiratoria.Pentacrom SL.1998:p.143-52.
Lazlo G. European standars for lung function testing:1993 update.
Thorax 1993;48:873-6.
Cleverley JR, Muller NL. Advances in radiologic assesment of chronic
obstructive pulmonary disease. Clin chest Med 2000;21:653-63.
Nicklaus TM, Stowel DW, Christiansen WR, Renzetti ADJr. The accuraty
of the roentgenologic diagnosis of chronic pulmonary emphysema.
Am Rev Respir Dis 1996;93:889-99.
Chetty KG, Brown SG, Light RW. Identification of pulmonary hypertension
in chronic obstructive pulmonary disease from routine chest radiographs.
Am Rev Respir Dis 1882;126:338-41.
MacNee W. Pathophysiology cor pulmonale in chronic obstructive pulmonary
disease .Am J Respir Crit Care Med 1994;150:1158-68.
Anthonisen NR, Wright EC, Hodking JE. Prognosis in chronic obstructive
pulmonary disease. Am Rev Respir Dis 1986;133:14-20
Nishimura K, Tsukino M. Clinical course and prognosis of patients
with chronic obstructive pulmonary disease. Curr Opin Pulm Med 2000;6:127-32.
Viejo Bañuelos JL.Tratamiento farmacológico e integrado
en la EPOC. En : Sobradillo V , editor.EPOC. Lo esencial. Barcelona:
MRA SL;1998;p.161-98.
Montemayor Rubio T,Ortega Ruiz F. Tratamiento farmacológico
en la enfermedad pulmonar obstructiva crónica.En : de Lucas
P, Peces-Barba G, editores. Enfermedad pulmonar obstructiva crónica.
Madrid:Editor SA;2001:p.117-31.
Pauwels RA, Lodahl CG, Laitinen LA, Scouten JP, Postma DE; Pride
NB, et al. Long-term treatment with inhaled budesonide in persons
with mild chronic obstructive pulmonary disease who continue smoking.
N Engl J Med 1999;340:1948-53.
Medical Research Council Working Party. Long-term domiciliary oxygen
therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis
and emphysema. Lancet 1981;1:681-5.
Sánchez Agudo L, Cornudella R, Estopa Miró R, Molinos
Martín L, Servera Pierás E.Normativa para la indicación
y empleo de la oxigenoterapia continuada domiciliaria (OCD ). Arch
Bronconeumol 1998;34:87-94.
De Lucas P, Güell Rous R, Sobradillo Peña V, Jimenez
Ruiz CA, Sangenis Pulido M, Montemayor Rubio T, et al.Normativa
sobre la rehabilitación respiratoria. Arch Bronconeumol 2000;36:257-74.
Martínez Riviera C, Izquierdo Ramírez J, Morera Prat
J. Manejo de las exacerbaciones de la EPOC. En : de Lucas P, Peces
-Barba G, editores. Enfermedad pulmonar obstructiva crónica.
Madrid:Editor SA;2001;p.133-59.
Bach PB, Brown C, Gelfand SE, MacCrory DC. Managent of accute exacerbations
of chronis obstructive pulmonary disease; a summary and appraisal
of published evidence. Ann Intern Med 2001;134:600-20.
Añón Elizalde JM, García de Lorenzo y Mateos
a, Alvarez-Sala Walter R, Escuela Gericó MP. Tratamiento
y pronóstico de la reagudización grave de la enfermedad
pulmonar obstructiva chrónica. Rev Clin Esp 2001;201:658-66.
Grainger J, Woodman K, Pearce N, Crane J, Burges C, Keane A, et
al. Prescribeb fenoterol and death from asthma in New Zeland. ¡981-7:
a further case-control study.Thorax 1991;46:105-11.
Jonhson M. The beta adrenoreceptor. Am J Respir Crit Care Med 1998;158:S146-53.
Brogden RN, Faulds D. Salmeterol Xinafoate: a review of its pharmacologycals
properties and therapheutic potencial in reversible obstructive
airways disease. Dugs 1991;42:895-912.
Lotwall J. Pharmacologycal similarities and differences between
beta-2 agonist. Respir Med 2001;95:S7-11.
Waldeck B. Some pharmacodynamics aspects of log-acting beta-adrenoceptor
agonist. Gen Pharmacol 1996;27:275-80.
Seelros O. Formoterol used as needed-clinical efectiviness. Respir
Med 2001;95:S17-20.
Woolcock A, Lundback BO, Ringdal N, Jacques LA. Comparison of addition
of salmeterol to inhalated steroids with doubling of the dose of
inhalated steroids. Am J Crit Care 1996;153: 1481-8.
Lipworth BJ. Optimizing bronchodilator therapy for COPD. Chest 2001;119:1628-30.
Bartow RA, Brogden RN. Formoterol. An update of its pharamacologycal
properties and trerapheutic efficaty in the management of asthma.
Drubs 1998;55:303-22.
Mann KV, Leon AL, Tietze KJ. Use of ipratropium bromide in obstructive
lung disease. Clin Pharm 1988;7:670-80.
Ferguson GT. Recommendattions for the management of COPD. Chest
2000;117:23S-8S.
Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge
SS, et al. Long-acting bronchodilation with one-daily dosing of
tiotropium ( spiriva ) in stable chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 2000;161:1136-42.
Gross NJ. Ipratropium bromide. N England J Med 1988;319:486-94.
Friedman M. Combined bronchodilator therapy in the management of
chronic obstructive pulmonary disease. Respirology 1997;2:S!9-23.
Calverley PMA. The future for tiotropium. Chest 2000;117:67S-9S.
Vassallo R, Lipsky JJ. Theophylline: recent avances in the understanding
of its mode of action and uses in clinical practice. Mayo Clin Proc
1998;73:346-54.
Cazzola M, Donner CF, Matera MG. Long acting beta-2 agonist and
theophylline in stable chronic obstructive pulmonary disease . Thorax
1999;54:730-6.
Anthonisen NR, Connet JE, Kiley JP, et al; Effect of smoking intervention
and the use of an inhaled anticholinergic bronchodilator on the
rate of decline of FEV1. JAMA 1994;272:1497-1505.
Sethi S.Infectious etiology of acute exacerbations of chronic bronchitis.
Chest 2000;117:S380-S385.
Soler N, Ewing S, Torres A. Airway inflammation and bronchial microbial
patterns in patients with stable chronic obstructive pulmonary disease
( COPD ). Eur Respir J 1999;14:1015-1020.
Niederman MS. Antibiotic therapy of exacerbations of chronic bronchitis.
Semin Respir Infect 2000;15:59-70.
Boughman RP, Pina E.Infections in the acute exacerbation of chronic
bronchitis : what are they and how do we know ¿ Sem Respir
Crit Care Med 2000;21:87-96.
Miratvilles M, Espinosa C, Fernández-Laso E. Relationship
between bacterial flora in sputum and funtional impairment in patient
with acute exacerbations of COPD. Chest 1999;116:40-46.
Research Committee of the British Thoracic Society. Smoking cesattion
in patients : two further studies by the British Thoracic Society.
Thorax 1990;45:835-840.
US Department of Health and Human Services. The health consequences
of smoking. Nicotine addiction: a report of the Surgeon General.
DHHS publication no ( CDC ) 88-8.406. Washington DC; US Govermment
Printing Office,1988.
Stapleton JA, Russell MAH, Feyerabend C, Wiseman S, Gustavsson G,
Sawe U, Wiseman D. Dose effect and predictors of outcome in a randomized
trial of transdermal nicotine patches in general practice. Addiction
1995;274:1353-1358.
The Smoking Cessation Clinical Practice Guideline Panel and Staff.
JAMA 1996;275:1270-80.
Cabezas MC. Novedades en la intervención sobre el consumo
de tabaco desde la atención primaria 2000;25:584-88.
Anthonisen NR, Manfreda J, Warren CPW, Hersfields ES, Harding GKM
, Nelson NA.Antibiotic therapy in exacerbations of chronic obstructive
pulmonary disease. Ann Intern Med 1987;106:196-204.
Ball P.Epidemiology and treatment of chronic bronchitis and its
excerbations. Chest 195;108:43S-52S.
Alphen LV, Jansen HM, Dankert J: Virulence factors in the colonization
and persistence of bacteria in the airways. An J Respir Crit Care
Med 1995;151:1094-100.
Baterman NT, Leach RM, ABC of Oxygen. Acute oxygen therapy. BMJ
1998;317:798-801.
Recomendaciones SEPAR. Indicaciones y empleo de la Oxigenoterapia
continua domiciliaria (OCD). Barcelona: Doyma; 1998.p.19-33.
Mosquera Pestaña JA, editor. Enfermedad pulmonar obstructiva
crónica. Actualización integrada. Madrid:Ergón;1997.
Viejo Bañuelos JL, Pueyo Bastida A, De Abajo Cucurull C.
Oxigenoterapia. Medicine 1997;7:2159-66.
|
